Prosecution Insights
Prosecution Insights
24 pending office actions • 11 clients • 22 examiners • 18 art units • 0 of 24 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 18 (75%) |
| §102 only | 1 (4%) |
| §112 only | 3 (12%) |
| No statute on record | 2 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIANG, SHIBIN | 2 | 62.8% | +17.0% |
| VAN DRUFF, SYDNEY | 2 | 56.4% | +29.5% |
| SHEN, YANXIN NMN | 1 | 100.0% | +0.0% |
| SPENCE, JENNIFER SUZANNE | 1 | 65.3% | +50.3% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.7% |
| BEE, ANDREW W. | 1 | 73.0% | +32.1% |
| KIM, YUNJU | 1 | 55.6% | +34.8% |
| PIERCE, JEREMY R | 1 | 56.6% | +43.0% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +38.6% |
| ZIMMERMAN, JOSHUA D | 1 | 40.5% | +15.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18848162 | Genetically Engineered Plants for Increased Production of Vindoline | SHEN, YANXIN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418537 | COMPOSITE STRUCTURE WITH POLYURETHANE LAYERS, WHICH IS SUBSTANTIALLY FREE OF VOLATILE ORGANIC COMPOUNDS | PIERCE, JEREMY R | 73d overdue |
| 17600887 | Method for Upgrading and Embossing Leather | LIANG, SHIBIN | 73d overdue |
| 18785206 | Method for Upgrading and Embossing Leather | LIANG, SHIBIN | 16d overdue |
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | VAN DRUFF, SYDNEY | 19d |
| 17262999 | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER | VAN DRUFF, SYDNEY | 26d |
| 18578066 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | HASTINGS, ALISON AZAR | 39d |
| 18689955 | Thermoformable Boron-Based Ceramic Material and Use in Thermal Management | KIM, YUNJU | 46d |
| 18719627 | Ex Vivo Production of Compounds of Interest | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1741 | 2 |
| 1798 | 2 |
| 1635 | 2 |
| 1718 | 2 |
| 1643 | 2 |
| 1663 | 1 |
| 1671 | 1 |
| 2677 | 1 |
| 1742 | 1 |
| 1789 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18848162 | Genetically Engineered Plants for Increased Production of Vindoline | Northeastern University | SHEN, YANXIN NMN | 1663 | §103 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18785206 | Method for Upgrading and Embossing Leather | Stahl International B.V. | LIANG, SHIBIN | 1741 | §103 | Non-Final OA | 16d overdue | Pending | Jul 26, 2024 |
| 18719627 | Ex Vivo Production of Compounds of Interest | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | SPENCE, JENNIFER SUZANNE | §103 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18643793 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | Agilent Technologies, Inc. | BLUMEL, BENJAMIN P | 1671 | §112 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18642362 | Posture-Based Infant Action Recognition System and Method | Northeastern University | BEE, ANDREW W. | 2677 | §103 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18689955 | Thermoformable Boron-Based Ceramic Material and Use in Thermal Management | Northeastern University | KIM, YUNJU | 1742 | §103 | Non-Final OA | 46d | Pending | Mar 07, 2024 |
| 18418537 | COMPOSITE STRUCTURE WITH POLYURETHANE LAYERS, WHICH IS SUBSTANTIALLY FREE OF VOLATILE ORGANIC COMPOUNDS | Stahl International B.V. | PIERCE, JEREMY R | 1789 | Other | Non-Final OA | 73d overdue | Pending | Jan 22, 2024 |
| 18578066 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | Northeastern University | HASTINGS, ALISON AZAR | 1627 | Other | Non-Final OA | 39d | Pending | Jan 10, 2024 |
| 18565980 | A MACHINE FOR EMBOSSING LEATHER | Stahl International B.V. | ZIMMERMAN, JOSHUA D | 2853 | §103 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18198397 | DEVICE AND METHOD FOR EXTRACTING CARDIOVASCULAR HEALTH STATUS BY USING OSCILLOMETRIC SIGNAL | Korea Advanced Institute Of Science And Technology | BLOCH, MICHAEL RYAN | 3791 | §112 | Final Rejection | — | Pending | May 17, 2023 |
| 18031486 | Engineered Cells for Increased Collagen Production | Northeastern University | MARVICH, MARIA | 1634 | §103 | Final Rejection | 9d overdue | Pending | Apr 12, 2023 |
| 18021447 | Microbe-Aided Perfusion System for Metallic Nanoparticle Production | Northeastern University | MUTREJA, JYOTI NAGPAUL | 1798 | §102 | Non-Final OA | 24d overdue | Pending | Feb 15, 2023 |
| 17925892 | Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells | Ixaka France | ARIETI, RUTH SOPHIA | 1635 | §103 | Final Rejection | 77d | Pending | Nov 17, 2022 |
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | Mitotech S.A. | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Non-Final OA | 45d overdue | Pending | Oct 03, 2022 |
| 17841465 | Flame Retardant Mechanical Foam | Stahl International B.V. | MAYY, MOHAMMAD | 1718 | §103 | Final Rejection | 30d overdue | Pending | Jun 15, 2022 |
| 17642789 | Inhibitor of metadherin expression | Firebrand Therapeutics, Inc. | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Mar 14, 2022 |
| 17613138 | Microfluidic Device for High-Throughput Screening of Tumor Cell Adhesion and Motility | Northeastern University | THOMPSON, CURTIS A | 1798 | §103 | Final Rejection | 8d | Pending | Nov 22, 2021 |
| 17608538 | Complex of Noble Metal Oxide Nanoparticles and Tellurium Nanowires and Biomedical Applications Thereof | Northeastern University | JOSEPH, JANET | 1611 | §103 | Final Rejection | 50d overdue | Pending | Nov 03, 2021 |
| 17600887 | Method for Upgrading and Embossing Leather | Stahl International B.V. | LIANG, SHIBIN | 1741 | §103 | Final Rejection | 73d overdue | Pending | Oct 01, 2021 |
| 17424636 | MXene Nanopore Sequencer of Biopolymers | Auburn University | OSMAN, SOMMER YOUSEF | 1794 | §103 | Non-Final OA | 74d overdue | Pending | Jul 21, 2021 |
| 17344035 | Freestanding Ultrathin Membranes and Transfer-Free Fabrication Thereof | Northeastern University | MCCLURE, CHRISTINA D | 1718 | §103 | Final Rejection | 22d | Pending | Jun 10, 2021 |
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | Curevac Netherlands B.V. | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 19d | Pending | Jan 26, 2021 |
| 17262999 | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER | Curevac Netherlands B.V. | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 26d | Pending | Jan 25, 2021 |
| 15908112 | MODIFIED POLY (BETA-AMINO ESTER)S FOR DRUG DELIVERY | Institut Químic de Sarrià | POPA, ILEANA | 1633 | §103 | Final Rejection | 8d | Pending | Feb 28, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial